I

Intuitive Surgical

Builds robots for minimally invasive surgery

Vice President Internal Audit

Full-Time
$270.4k - $405.6k/yr+ Incentives + Equity
Expert
Bachelor's, MBA
Sunnyvale, CA, USA
HybridTuesday through Thursday in the office weekly, with Monday and Friday as needed; approximately 25% domestic and international travel is expected.
AccountingAuditing

About the job

Requirements
  • A minimum of 18 years of progressive audit, finance, and/or operational experience, including at least 10 years leading internal audit or public accounting teams at large, complex organizations.
  • Demonstrated experience as a senior audit leader, including direct Audit Committee and Board-level communication.
  • Deep knowledge of International Standards for the Professional Practice of Internal Auditing Standards, the Committee of Sponsoring Organizations of the Treadway Commission framework, Sarbanes-Oxley Act Section 404 requirements, and Public Company Accounting Oversight Board audit standards.
  • A proven track record of developing and executing comprehensive, risk-based global audit plans across financial, operational, information technology, and compliance domains.
  • Strong business acumen and the ability to quickly assimilate complex business processes, emerging risks, and strategic priorities across a global, multi-segment technology company.
  • Executive presence and communication skills sufficient to influence and advise the Board, executive leadership team, and operational management levels with clarity, credibility, and candor.
  • Experience leading and developing high-performing teams, with the ability to attract, develop, and retain top talent.
  • Familiarity with information technology audit, cybersecurity risk, and data analytics methodologies, including the ability to direct and oversee information technology and information systems audit engagements.
  • Experience in the medical device, life sciences, or healthcare technology industry, with an understanding of relevant regulatory frameworks strongly preferred.
  • Demonstrated ability to manage third-party co-sourcing relationships, coordinate with external auditors, and conduct mergers and acquisitions due diligence activities.
  • A bachelor's degree (BA/BS) in Accounting, Finance, or a closely related field is required.
  • A Certified Public Accountant or Certified Internal Auditor certification is required.
Responsibilities
  • Maintain functional independence and report to the Audit Committee of the Board of Directors.
  • Develop and champion the long-range strategic vision for the Internal Audit function.
  • Prepare and present quarterly and ad hoc reports to the Audit Committee, including risk assessment results, audit plan status, key themes, emerging risks, and departmental performance metrics.
  • Advise the Chief Financial Officer, Chief Executive Officer, and senior leadership on governance, risk, and internal controls, including advisory projects, mergers and acquisitions due diligence, and strategic initiatives.
  • Participate in Enterprise Risk Management programs by providing Internal Audit’s independent perspective on the company’s top risks.
  • Lead the development, continuous evaluation, and Board-level approval of a dynamic, risk-based global annual audit plan.
  • Integrate internal and external risk intelligence to keep the audit plan responsive and prioritized on the highest-risk areas.
  • Oversee mergers and acquisitions due diligence activities and post-integration audits.
  • Direct and oversee fraud risk assessment and investigation activities in partnership with Legal and Compliance.
  • Oversee end-to-end execution of the approved audit plan across operational, financial, Sarbanes-Oxley Act Section 404, information technology and cybersecurity, and regulatory compliance engagements.
  • Maintain the Internal Audit function in full conformance with International Standards for the Professional Practice of Internal Auditing Standards and establish a Quality Assurance and Improvement Program.
  • Direct the company’s Sarbanes-Oxley Act Section 404 compliance program in coordination with the Corporate Controller, information technology, and external auditors.
  • Oversee third-party co-sourcing and outsourcing relationships supporting audit plan execution.
  • Track audit findings and management action plans to timely remediation, with escalation protocols for unresolved critical issues.
  • Build and sustain relationships with executive management, the Audit Committee, external auditors, and regulators while maintaining objectivity and independence.
  • Communicate complex risk and control issues in clear, actionable terms to the Board and operational management.
  • Coordinate with second-line assurance functions to ensure comprehensive and non-duplicative risk coverage across the three lines of defense model.
  • Coordinate with external auditors to align Sarbanes-Oxley reliance strategies, coordinate coverage, and maximize assurance efficiency.
  • Lead, inspire, and develop a high-performing internal audit team.
  • Recruit, develop, and retain audit talent; build a succession pipeline; and ensure the team has the required skills, certifications, and industry expertise.
  • Define and manage the Internal Audit department budget, workforce plan, and resource allocation.
  • Drive adoption of data analytics, audit automation, continuous monitoring, and emerging technologies, including artificial intelligence-enabled tools.
  • Advocate for stronger information technology general controls, cybersecurity posture, and data governance practices.
Desired Qualifications
  • Prior experience as Chief Audit Executive or Vice President of Internal Audit at a publicly traded, global medical device, technology, or life sciences company.
  • A track record of building or significantly transforming an internal audit function, including implementing data analytics, continuous monitoring, or audit automation programs.
  • Experience supporting or managing robotics, digital health, or capital equipment business models with complex revenue recognition and service or leasing considerations.
  • Prior experience working with a Big Four public accounting firm in an audit or advisory capacity.
  • Working knowledge of international tax risk, transfer pricing, and Foreign Corrupt Practices Act and anti-bribery compliance from an audit oversight perspective.
  • Demonstrated success integrating acquired companies from an internal controls and audit standpoint.
  • Familiarity with artificial intelligence-enabled audit tools and advanced data analytics methodologies.
  • A Master of Business Administration or equivalent advanced degree.
  • Additional certifications such as Certified Information Systems Auditor, Certified Fraud Examiner, or Certification in Risk Management Assurance.

About the company

Intuitive Surgical makes da Vinci robots that let surgeons operate through a few small incisions, and Ion, a robot that reaches deep into the lungs to take tissue samples. In 2000, da Vinci became the first robotic system cleared by the FDA for general laparoscopic surgery, meaning keyhole operations in the abdomen. A surgeon sits at a nearby console and steers robotic arms holding a 3D camera and wristed instruments, which turn hand movements into smaller, steadier motions. Hospitals buy or lease the robots, then keep paying for the instruments used in each operation and for service. Intuitive was founded in 1995 to commercialize robotic surgery research from SRI International and is based in Sunnyvale, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Sunnyvale, California

Founded

1995

Get referred to Intuitive Surgical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Demand keeps compounding: da Vinci procedures grew 15% and revenue 19%, to $2.89 billion, in the June 2026 quarter.
  • Room to grow: Intuitive listed 748 open roles in October 2026, including 191 in engineering and 312 in Sunnyvale.
  • Repeat sales steady the business: instruments and service made 76% of revenue in the June 2026 quarter.

What critics are saying

  • Stock grants have shrunk: shares fell 27% from January to October 2026, versus 9% for rival Medtronic.
  • Device giants are moving in: the FDA cleared rival robots from Medtronic in December 2025 and J&J in July 2026.
  • Instrument sales face a court fight: in August 2026, an appeals court revived a repair firm's monopoly suit against Intuitive.

What makes Intuitive Surgical unique

  • Hospitals rent more than they buy: 254 of 468 da Vinci systems placed in the June 2026 quarter were leases.
  • It runs without borrowing: Intuitive had no debt and $8.6 billion in cash and investments in June 2026.
  • Its CEO is a 30-year insider: Dave Rosa, CEO since July 2025, joined as employee number nine in 1996.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Oct 1st, 2026
Intuitive Surgical down 30% in 2026, but Wall Street analysts stay bullish

Intuitive Surgical has lost nearly 30% year-to-date in 2026, making it one of healthcare's biggest losers. The stock fell over 40% by late July. Despite this decline, Wall Street remains bullish—24 of 32 analysts surveyed by S&P Global in September rated it a "buy" or "strong buy." The medical device maker faces several challenges. Growth is slowing whilst the stock trades at a forward price-to-earnings multiple over 33. Competition in China remains difficult, and the company now battles healthcare giants Johnson & Johnson, Medtronic, and Stryker in robotic surgical systems. The expiration of Affordable Care Act subsidies and rising GLP-1 drug usage have also impacted procedure volumes. However, the company's Asian revenue still jumped 20% year-over-year in Q2, suggesting these headwinds aren't insurmountable.

Yahoo Finance
Sep 17th, 2026
Intuitive Surgical, IonQ, and Accenture hold billions in net cash for growth

Investors seeking financial stability often look to companies with more cash than debt, as these businesses have greater flexibility for growth investments, buybacks, and dividends. Intuitive Surgical holds $5.22 billion in net cash. The robotic surgery pioneer achieved 20.7% annual revenue growth over the past two years, whilst its earnings per share increased 17.4% annually over five years. IonQ maintains $2.06 billion in net cash, representing 14.1% of its market capitalisation. The quantum computing company posted 181% annual revenue growth over two years and expects 163% growth next year. Accenture has $1.78 billion in net cash. The professional services firm employs approximately 774,000 people across more than 120 countries. Companies with strong balance sheets can navigate uncertain markets whilst pursuing expansion opportunities without the burden of significant debt obligations.

Yahoo Finance
Aug 23rd, 2026
Thermo Fisher vs Intuitive Surgical: which premium healthcare stock justifies valuation?

Thermo Fisher and Intuitive Surgical both delivered strong recent quarters, but their premium valuations rest on different foundations. Thermo Fisher's case depends on recovery in life sciences spending after the pandemic slowdown. The company's Life Sciences Solutions segment saw reported revenue climb 13% year-over-year, with organic revenue up 3%. The Analytical Instruments business returned to growth after nearly two years of weak demand, suggesting laboratory spending is normalising. Intuitive Surgical maintains its premium through business model strength. The company's non-GAAP gross profit margin reached 70.0%, whilst its non-GAAP operating margin expanded 330 basis points year-over-year to 42.1%. Recurring revenue streams constitute roughly 85% of total sales. Intuitive placed 468 da Vinci surgical units in fiscal Q2, marking 18% year-over-year growth, indicating continued hospital investment in robotic surgery platforms.

Yahoo Finance
Aug 19th, 2026
Abbott beats Q2 estimates with 13% sales growth as diagnostics surge 42%, while Intuitive Surgical posts 19% revenue rise

Abbott Laboratories reported strong fiscal Q2 2026 results, with sales rising 13% on a reported basis and 4.8% on a comparable basis, beating estimates and prompting the company to raise its annual profit forecast. The diagnostics segment was particularly strong, growing 42% to $3.09 billion, driven by its cancer diagnostics business following the Exact Sciences acquisition. Intuitive Surgical also exceeded expectations in Q2 2026, with revenue growing 19% to $2.89 billion and adjusted EPS of $2.80, beating forecasts by $0.30. The company placed 468 da Vinci units during the quarter, an 18% year-over-year increase, whilst maintaining a non-GAAP gross margin of 70.0%. The companies present contrasting investment cases: Abbott offers diversified healthcare portfolio resilience, whilst Intuitive Surgical relies on its robotic surgery ecosystem with recurring revenue comprising approximately 85% of total sales.

PR Newswire
Aug 17th, 2026
Intuitive leases 316,000-sq-ft facility in Penang to manufacture surgical instruments, create 1,200 jobs by 2032

Intuitive, the global leader in minimally invasive care and pioneer of robotic-assisted surgery, has signed a lease agreement with Penang Development Corporation for a new manufacturing facility in Malaysia. The 316,000-square-foot site in Bandar Cassia Technology Park will produce surgical instruments and electromechanical devices for Intuitive's da Vinci surgical system. The facility is expected to begin operations in 2028 and create 1,200 highly skilled jobs by 2032. The investment reflects Intuitive's commitment to Asia Pacific, where its da Vinci systems have treated more than 2.5 million patients across 13 markets over two decades. The expansion aims to support growing demand for robotic-assisted surgery across the region and strengthen Penang's position as a MedTech manufacturing hub in Southeast Asia.